In a mouse model, silencing Pcsk7 expression in hepatocytes through hepatocyte-specific N-acetylgalactosamine (GalNac) modified antisense oligonucleotides (ASOs) significantly improved the non-alcoholic fatty liver disease(NAFLD) phenotype. Here, PCSK7 is linked to metabolic dysfunction-associated steatotic liver disease.